Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CLN-619 · 2 trials · 3 indications
Incidence of AEs and SAEs using MedDRA
ECOG Scores are a functional scale ranging from 0 (Fully active, able to carry out all pre-disease activities without restrictions) to 5 (Death)
Maximum Tolerated Dose (MTD) is reached if 2 or more patients experience a DLT at a dose level
The best response defined by the International Myeloma Working Group (IMWG) criteria recorded throughout the study including unscheduled assessments
The proportion of patients who achieve a partial response or better (e.g., Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR) or stringent Complete Response (sCR), according to IMWG response criteria
The time from the earliest date of documented response to the first documented disease progression or death, whichever occurs first.
The proportion of patients with a best overall response of CR, PR and stable disease (SD), according to IMWG response criteria
The time from date of first dose until the earliest date of disease progression, or death from any cause, whichever occurs first.
Time from the date of first dose to date of death due to any cause.
Number of treatment-emergent events (TEAEs) TEAE is defined as adverse events reported for the first time or worsening of a pre-existing event after the first dose of study drug.
The percentage of patients having a CR or PR as determined by PI assessment of disease response per RECIST 1.1 on at least one scan.
The percentage of patients having a CR or PR as determined by PI assessment of disease response per RECIST 1.1.
The time from the earliest date of CR or PR until the earliest date of disease progression, as determined by PI assessment of disease response per RECIST 1.1 or death from any cause if occurring sooner than progression.
The percentage of participants having CR, PR, or SD as best on study response.
Time from the initial date of treatment until death.
The percentage of participants who achieve CR, PR or SD for a duration of 6 months as determined by PI assessment of disease response per RECIST 1.1.
| Arm | Type | Description |
|---|---|---|
| Part 1 Dose Escalation | EXPERIMENTAL | Cohorts of patients with R/R MM will be treated at ascending doses of CLN-619 using a standard 3+3 dose escalation design. |
| Module A Dose Escalation | EXPERIMENTAL | Patients with advanced solid tumors enrolled in dose escalation cohorts treated with CLN-619 |
| Module A Cohort Expansion | EXPERIMENTAL | Patients with select solid tumor types enrolled in expansion cohorts treated with CLN-619 at a dose selected from the Module A Escalation arm |
| Module B Combination Therapy Dose Escalation | EXPERIMENTAL | Patients with advanced solid tumors enrolled in dose escalation cohorts treated with CLN-619 in combination with pembrolizumab |
| Module B Combination Therapy Cohort Expansion | EXPERIMENTAL | Patients with select tumor types enrolled in expansion cohorts treated with CLN-619 at a dose selected from the Module B Escalation arm, in combination with pembrolizumab |
| Module C Escalation and Expansion | EXPERIMENTAL | Patients with select tumor types taking CLN-619 in combination with chemotherapy |
| Module D Loading Dose | EXPERIMENTAL | Patients with select tumor types taking a loading dose of CLN-619 |
| Module E Safety Run-in and Expansion | EXPERIMENTAL | Patients with select NSCLC tumor types taking CLN-619 in combination with Dato-DXd |
| Name | Type | Description |
|---|---|---|
| CLN-619 | DRUG | Anti-MICA/MICB monoclonal antibody |
| Pembrolizumab | DRUG | Keytruda |
| Paclitaxel | DRUG | Taxane |
| Carboplatin AUC 6 | DRUG | Platinum compound |
| pemetrexed | DRUG | antifolate |
| Datopotamab deruxtecan-dlnk (Dato-DXd) | DRUG | TROP-2 antibody-drug conjugate (ADC) |
Inclusion Criteria: 1. Aged ≥ 18 years at the time of signing the ICF. 2. Willing and able to give written informed consent and adhere to protocol requirements. 3. Patient has a history of multiple myeloma with relapsed and refractory disease as defined by the protocol. 4. Patients must have measur...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CLN-619 is an investigational small molecule being studied for advanced solid tumors, including non-small cell lung cancer (NSCLC), and for relapsed and refractory multiple myeloma. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
CLN-619 targets MICA/B, a protein involved in the immune response to tumors. By targeting MICA/B, the drug is designed to enhance the body's ability to fight cancer cells. This mechanism is being evaluated in clinical trials for advanced solid tumors and multiple myeloma.
CLN-619 is being developed by Cullinan Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol CGEM. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
CLN-619 is in Phase 1 clinical development. It is being studied in two active trials: one for advanced solid tumors and NSCLC, and another for relapsed and refractory multiple myeloma. The drug is investigational and has not received FDA approval.
CLN-619 is being evaluated in two Phase 1 trials. NCT05117476 studies CLN-619 alone and in combination with pembrolizumab in advanced solid tumors, including NSCLC, with 440 participants across the US, Australia, Poland, and Spain. NCT06381141 studies CLN-619 in relapsed and refractory multiple myeloma with 30 participants in the US.
CLN-619 is described as an anti-MICA/MICB antibody in the clinical trial for multiple myeloma. It targets MICA/B proteins. The drug is being investigated for its potential to treat advanced solid tumors and multiple myeloma, but it is not yet approved for any indication.